tiprankstipranks
Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ:TARS
US Market
TARS
Tarsus Pharmaceuticals
RESEARCH TOOLSreports
Want to see TARS full AI Analyst Report?

Tarsus Pharmaceuticals (TARS) Stock News & Sentiment

267 Followers
Tarsus Pharmaceuticals Earnings Call Signals Durable Growth
Premium
Company Announcements
Tarsus Pharmaceuticals Earnings Call Signals Durable Growth
5h ago
TARS
3 Best Growth Stocks to Buy in May 2026, According to Analysts
Premium
Market News
3 Best Growth Stocks to Buy in May 2026, According to Analysts
2d ago
NFLX
PANW
Buy Rating Reaffirmed on XDEMVY as Inventory Dynamics Seen as Transient and $88 Price Target Remains Unchanged
Premium
Ratings
Buy Rating Reaffirmed on XDEMVY as Inventory Dynamics Seen as Transient and $88 Price Target Remains Unchanged
3d ago
TARS
Buy Rating Backed by Blockbuster Xdemvy Launch and TP-05 Lyme Prevention Opportunity
Premium
Ratings
Buy Rating Backed by Blockbuster Xdemvy Launch and TP-05 Lyme Prevention Opportunity
1M ago
TARS
Tarsus Pharmaceuticals Bets Big on XDEMVY Growth
Premium
Company Announcements
Tarsus Pharmaceuticals Bets Big on XDEMVY Growth
2M ago
TARS
Sustained Growth Outlook for Tarsus Driven by XDEMVY’s Rapid Ramp and Expanding Lotilaner Pipeline
Premium
Ratings
Sustained Growth Outlook for Tarsus Driven by XDEMVY’s Rapid Ramp and Expanding Lotilaner Pipeline
2M ago
TARS
Tarsus: Strong Xdemvy Launch, Upgraded Long‑Term Outlook, and Underappreciated Earnings Power Support Buy Rating
Premium
Ratings
Tarsus: Strong Xdemvy Launch, Upgraded Long‑Term Outlook, and Underappreciated Earnings Power Support Buy Rating
2M ago
TARS
More TARS News >

TARS News on the Web

Tarsus Pharmaceuticals Stock Sinks Amid Market Jitters
TipRanks News
Bearish
Analysts Offer Insights on Healthcare Companies: Alterity Therapeutics (OtherPRNAF), Tarsus Pharmaceuticals (TARS) and enGene Holdings (ENGN)
TipRanks News
Bullish
Tarsus Pharmaceuticals (TARS) Receives a Buy from LifeSci Capital
TipRanks News
Bearish
Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS) and Forte Biosciences (FBRX)
TipRanks News
Neutral
Buy Rating Backed by Blockbuster Xdemvy Launch and TP-05 Lyme Prevention Opportunity
TipRanks News
Bullish
Tarsus Pharmaceuticals doses first participant in TP-05 trial
TipRanks News
Bullish
Barclays Reaffirms Their Buy Rating on Tarsus Pharmaceuticals (TARS)
TipRanks News
Neutral
Analysts’ Top Healthcare Picks: Tarsus Pharmaceuticals (TARS), IDEAYA Biosciences (IDYA)
TipRanks News
Neutral

News Score - Last 7 Days

Negative
TARS
Sector Average
Media Buzz
This Week1 articles
Weekly Average4.75 articles
News Sentiment
This Week0%
Sector Average70%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is TARS’s Media Buzz Sentiment?
1 articles about TARS were published this week. In an average week, 4.75 articles are published.
    What is TARS’s weekly average amount of articles?
    In an average week, 4.75 articles about TARS are published.
      What is TARS’s News Sentiment?
      Currently, no data Available
      Healthcare Stocks that are Trending in the News
      TVTXTravere Therapeutics
      HVOOpen Orphan Plc
      PBMPsyence Biomedical
      QDELQuidelOrtho
      Showing the stocks with the most bullish news sentiment over the past week